Drug name…or Star Wars planet?
Prescription drugs have weird names. But so do planets in the Star Wars universe. We asked CNBC staffers whether they could tell the difference.
02:04
Fri, Apr 10 20159:30 AM EDT
Similar Posts
Uncertainty around Russia could cause severe spike in oil, says Paul Sankey
Paul Sankey, lead analyst at Sankey Research, joins ‘The Exchange’ to discuss oil prices.
Rep. French Hill on bitcoin ETF approval: We need a change in the ‘regulatory posture’ in Washington
House Financial Services Committee vice chairman and Digital Assets Committee chairman Rep. French Hill (R-Ark.) joins ‘Squawk Box’ to discuss the SEC’s approval of spot bitcoin ETFs, what it means for crypto regulation in Congress, and more.
Hopes for ‘accelerated’ stimulus are driving stocks higher: Strategist
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Investors seem to be expecting a “massive” stimulus from the Democratic sweep of Congress, according to Jim Lowell, CIO of Adviser Investments. 00:00 Fri, Jan 8 20212:43 AM EST
CNBC PRO Talks: Morningstar’s chief U.S. strategist on stocks to beat the volatility
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Dave Sekera, chief U.S market strategist for Morningstar, joined CNBC’s Julianna Tatelbaum on Wednesday for a frank conversation on the market outlook. 33:50 Wed, Jul 13 20229:16 AM EDT
Watch CNBC’s full interview with Charles Schwab’s Liz Ann Sonders, Veritas’ Greg Branch and Virtus’ Joe Terranova
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Liz Ann Sonders, Charles Schwab chief investment strategist, Greg Branch, Veritas Financial Group managing partner, and Joe Terranova, senior managing director at Virtus Investment Partners, join ‘Closing Bell’ to discuss the CPI report, jobs data impact on the markets, and more.
Mega cap momentum concerns: What you need to know
The Investment Committee debates tech stocks as valuation concerns threaten to snap the NASDAQ’s four-day win streak.
